JPMorgan Upgrades Biogen to Overweight with $300 Price Target on Strong Pipeline Catalysts in 2027
Biogen (BIIB) shares rose by 2.1% during premarket trading after JPMorgan upgraded the stock from neutral to overweight, citing a strong pipeline of catalysts expected in 2027 as key drivers for growth. The brokerage set a price target of $300 per share on Biogen, implying a potential increase of approximately 33% from its last closing price. This upgrade reflects confidence in the company's future developments and their impact on long-term value creation.
Tickers: $BIIB
Topics: analyst rating change pipeline catalysts stock upgrade